Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Short-term Investments: 2010-2024

Historic Short-term Investments for Vanda Pharmaceuticals (VNDA) over the last 15 years, with Dec 2024 value amounting to $272.3 million.

  • Vanda Pharmaceuticals' Short-term Investments fell 18.87% to $223.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $223.7 million, marking a year-over-year decrease of 18.87%. This contributed to the annual value of $272.3 million for FY2024, which is 7.88% up from last year.
  • According to the latest figures from FY2024, Vanda Pharmaceuticals' Short-term Investments is $272.3 million, which was up 7.88% from $252.4 million recorded in FY2023.
  • In the past 5 years, Vanda Pharmaceuticals' Short-term Investments ranged from a high of $380.7 million in FY2021 and a low of $252.4 million during FY2023.
  • Its 3-year average for Short-term Investments is $285.5 million, with a median of $272.3 million in 2024.
  • Its Short-term Investments has fluctuated over the past 5 years, first climbed by 24.14% in 2021, then dropped by 23.92% in 2023.
  • Yearly analysis of 5 years shows Vanda Pharmaceuticals' Short-term Investments stood at $306.7 million in 2020, then rose by 24.14% to $380.7 million in 2021, then fell by 12.85% to $331.8 million in 2022, then dropped by 23.92% to $252.4 million in 2023, then grew by 7.88% to $272.3 million in 2024.